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Abstract
AIMS: Nodal spread is the single most important prognostic factor of survival in gastric cancer patients. In this
study, genes that were upregulated in the lymph node metastases of gastric cancer were identified and may serve
as putative novel therapeutic target. METHODS: Complementary DNA (cDNA) microarray analysis and quantitative
real-time polymerase chain reaction of primary gastric carcinomas and matched lymph node metastasis were car-
ried out. Immunohistochemistry with anti-SPARC antibodies was performed on large tissue sections of 40 cases
with primary gastric carcinoma (20 diffuse, 20 intestinal) and the corresponding lymph node metastases, as well as
on tissue microarrays of 152 gastric cancer cases. RESULTS: A cDNA microarray identified SPARC as being up-
regulated in primary gastric carcinoma tissue and the corresponding lymph node metastasis compared with the
nonneoplastic mucosa. SPARC was expressed in fibroblasts and, occasionally, in tumor cells. However, the level
of immunoreactivity was particularly strong in stromal cells surrounding the tumor. The level of expression of
SPARC, determined by immunohistochemistry, correlated in intestinal-type gastric cancer with the local tumor
growth, nodal spread, and tumor stage according to the International Union Against Cancer. CONCLUSIONS:
Our study provides transcriptional and translational evidence for the differential expression of SPARC in gastric
cancer tissue. On the basis of our observations and those made by others, we hypothesize that SPARC is a prom-
ising novel target for the treatment of gastric cancer.
Translational Oncology (2009) 2, 310–320
Introduction
Gastric cancer is the fourth most common cancer and the second
leading cause of cancer-related deaths worldwide surpassed only by
lung cancer [1,2]. Among various prognostically relevant variables
of gastric cancer, the lymph node status and the ratio of metastasis-
positive/metastasis-negative lymph nodes are the strongest markers of
gastric cancer prognosis [3,4]. The N-ratio (metastatic/examined lymph
nodes) has been validated as an independent prognostic factor in a large
multicenter series, even where less than the recommended 15 lymph
nodes have been examined [5,6]. The 5-year survival rate for patients
with metastases in 1 to 6 lymph nodes is 44% and drops to 30% for
7 to 15 lymph node metastases, ending with 11% for more than 15
lymph node metastases. Unfortunately, most patients presenting with
advanced gastric cancer already have lymph node metastases [7]. Gas-
trectomy with or without accompanying adjuvant radiotherapy and/or
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chemotherapy is the treatment of choice, promising complete cure in
early stages. However, more than half of the patients receiving potential
curative surgery will finally experience relapse. For them and for most
patients presenting with advanced disease stages, the therapeutic options
are systemic chemotherapy, radiotherapy, or both [1]. Because the cur-
rently used chemotherapeutic regimens and radiotherapy have limited
efficacy in the metastatic stage, in this patient group, therapy-resistant
disease progression usually leads to tumor-related death within a year.
This underscores the urgent need for novel therapeutic targets in the
treatment of gastric cancer, and identifying factors contributing to nodal
spread may help to improve gastric cancer prognosis. Using a gene
array–based approach, genes that were upregulated in the lymph node
metastases of gastric cancer were identified, and the differential expres-
sion was confirmed by quantitative reverse transcription–polymerase
chain reaction (RT-PCR) and immunohistochemistry. Using tissue
microarrays (TMAs), we demonstrate on a larger patient series that
SPARC is differentially expressed in gastric cancers and that its expres-
sion correlates with tumor progression and nodal spread. Hence, target-
ing SPARCmay be a novel treatment target for metastatic gastric cancer.
Materials and Methods
Patient Characteristics and Tissue Samples
For histologic and immunohistochemical studies, formalin-fixed
(10% neutralized formalin) and paraffin-embedded tissue samples
from the archive of the Department of Pathology of the University of
Magdeburg were obtained from 174 gastric cancer patients (105 men
and 68 women), who had undergone either complete or partial gas-
trectomies between 1995 and 2005. The age of the patients ranged
from 26 to 84 years (mean = 64.6 ± 11.9 years). For molecular bio-
logic studies, unfixed tissue samples from the nonneoplastic mucosa,
primary tumor, and the corresponding lymph node metastases were
collected immediately after surgery from six patients with gastric
cancer, shock-frozen in liquid nitrogen, and stored at −80°C until
further use. Gastric cancer was classified according to Laurén [8].
The tumor (T category), node (N category), andmetastasis (M category)
stage was determined according to the International Union Against
Cancer (UICC) guidelines and was based on histologic confirmation
using hematoxylin and eosin–stained sections [9]. All cases were re-
viewed before study inclusion. This study is in accordance with the
guidelines of the local ethics committee. Data were encoded to ensure
patient protection.
Cell Culture
The human gastric cancer cell lines AGS, KATOIII, MKN28,
MKN45, and NCI-N87 were obtained from the Riken Cell Bank
(Tsukuba, Japan) and American Type Culture Collection (Rockville,
MD). Cell lines were maintained in RPMI-1640 medium (PAA Lab-
oratories, Cölbe, Germany), supplemented with 10% fetal calf serum
(PAA Laboratories). The cells were grown in a tissue culture hood at
37°C with 5% carbon dioxide atmosphere. Cells were washed with
phosphate-buffered saline (Sigma, Deisenhofen, Germany) and har-
vested with Trypsin-EDTA (PAA Laboratories).
Gene Array Analyses
For the gene array, large tissue samples from a single site were used
each from the primary gastric cancer (poorly differentiated intestinal-
type gastric cancer; pT3 pN3 pMX) and a large corresponding lymph
node metastasis (>1.5 cm diameter) of a 69-year-old male white pa-
tient. After extraction of RNA using the RNeasy Kit (Qiagen, Hilden,
Germany), the preparation and labeling of the complementary DNA
(cDNA) (LabelStar; Qiagen) was carried out according to the LabelStar
Array Handbook (Qiagen). Briefly, 20 μg of total RNA in 20 μl of
RNase-free H2O was incubated at 65°C and added to 5 μl of 10×
reverse transcriptase buffer, 5 μl of dNTP mix C, 1 μl of cyanine 3–
or cyanine 5–labeled dCTP, 5 μl of oligo-dT primer, 0.5 μl of RNase
inhibitor, 2.5 μl of LabelStar reverse transcriptase in a total volume of
50 μl. After incubating at 37°C for 120 minutes, the reaction was
stopped, and the labeled cDNAwas purified according to the manufac-
turer’s instructions. Hybridization of the labeled cDNAwith the cDNA
gene array (Human 10k Array A;MWG-Biotech, Ebersberg, Germany)
was performed in cyanine 3 and cyanine 5 hybridization buffer. The
samples were incubated overnight and washed and dried the next
day. Arrays were then evaluated using the GenePix 4000B microarray
scanner by means of the GenePix Pro 4.0 Software (Axon Instruments
Europe GmbH, Hamburg, Germany).
RNA Extraction and cDNA Synthesis
Total RNA was extracted from tumor and nonneoplastic tissue
samples using the RNeasy Kit from Qiagen following the recom-
mended protocol. The resulting RNA was quantified spectrophoto-
metrically using a GeneQuant (Pharmacia LKB, Freiburg, Germany)
and stored at −80°C until further required. One microgram of total
RNA was transcribed into cDNA using Omniscript Reverse Tran-
scriptase (Qiagen) according to the recommended protocol. SPARC
and β-actin PCR products were amplified using the Taq PCR Core
Kit (Qiagen) and specific primer (SPARC: forward: 5′-AAG ATC CAT
GAG AAT GAG AAG-3′, reverse: 5′-AAA AGC GGG TGG TGC
AAT G-3′; β-actin: forward: 5′-CAT GTA CGT TGC TAT CCA
GGC-3′, reverse: 5′-CTC CTT AAT GTC ACG CAC GAT-3′): 2 μl
of cDNAwas amplified with 10 μl of 10× PCR buffer, 0.4 μl of dNTPs,
1 μl of each primer, 4 μl of Q-solution, and 0.1 μl of Taq polymerase
and the following temperature profile: at 95°C for 5 minutes; 40× (at
94°C for 30 seconds, at 53°C for 60 seconds, and at 72°C for 30 sec-
onds); and at 72°C for 10 minutes.
Fluorescence-Mediated Quantitative Real-time RT-PCR
Fluorescence-mediated quantitative real-time RT-PCR was per-
formed using the Lightcycler (RocheDiagnostics,Mannheim,Germany).
External standards were established by purifying the appropriate PCR
product using the Nucleospin Extract II kit (Macherey & Nagel, Düren,
Germany) as instructed. The PCR product DNAwas quantified spectro-
photometrically, and the copy number of the PCR products was cal-
culated. Serial dilutions of the purified DNA samples were used as
external standards in every run to create a standard curve for the calcula-
tion of mRNA levels. Quantitative RT-PCR was performed using the
SYBR Green Two-Step RT-PCR Kit (Qiagen). All reactions contained
2 μl of the cDNA template, primer (see above), and 10 μl of the 2 ×
PCR buffer in a final volume of 20 μl. A hot start for 15 minutes at
95°C to activate the Taq polymerase was followed by 35 cycles, each with
a denaturation at 94°C for 15 seconds, annealing at 54°C for 20 seconds,
and extension at 72°C for 15 seconds. Melting curve analysis of the am-
plified products was performed between 65°C and 95°C and verified the
absence of substantial side products. The fluorescence intensity of the
double-strand–specific SYBR Green I, reflecting the amount of actually
formed PCR product, was measured at the end of each cycle during
the 72°C elongation step (previousmelting curve analyses had determined
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the melting points of the PCR products). The time point at which the
linear increase of PCR product started (threshold cycle) was determined
for each sample. Using the threshold cycle values, the mRNA copy num-
ber was calculated from the standard curve (serial dilutions of the
corresponding PCR product). The expression levels of β-actin were calcu-
lated in the same manner and used to normalize cDNA contents for any
variability in RNA amounts or integrity.
Tissue Microarray
For the evaluation of SPARC expression, TMAs were generated
using a precision instrument (Beecher Instruments, Silver Spring,
MD) as described previously [10]. In brief, a minimum of 6 tissue
cylinders of 0.6 mm in diameter were punched randomly from each
tumor-bearing donor block and 12 tissue cylinders (six from antrum
and six from corpus mucosa) from corresponding nonneoplastic mu-
cosa, constructing 20 blocks of TMAs. Overall, 6.1 ± 2.7 spots per
carcinoma from different tumor areas were eligible for analysis, re-
sulting in a total of 2617 spots scored for SPARC expression.
Immunohistochemistry
For immunostaining of paraffin-embedded sections, the slides
were deparaffinized and rehydrated in a graded alcohol series. Immuno-
staining was performed with an antibody directed against SPARC
(monoclonal mouse, dilution 1:900; Takara Bio, Inc, Otsu, Japan).
After antigen retrieval (1 mM EDTA, 12 minutes, 8 minutes, 450 W),
incubation with the primary antibody was carried out in a moist cham-
ber at 37°C for 1 hour. Biotinylated polyvalent antimouse/antirabbit
immunoglobulin G (Immunotech, Marseilles, France) served as a sec-
ondary antibody (30 minutes at room temperature). Slides were washed
between steps with Tris-buffered saline. Immunoreactions were visual-
ized through an avidin-biotin complex, using the Vectastain ABC
Alkaline Phosphatase Kit (distributed by CAMON, Wiesbaden, Ger-
many), with Fast Red/Naphthol Mx (Immunotech) as chromogen. The
specimens were counterstained with hematoxylin. Omission of primary
antibodies served as negative controls. Sections were evaluated by an
experienced pathologist, and a score was applied to quantify the extent
of expression: 0 = no expression, 1 = low expression, 2 = moderate
expression, 3 = strong expression. For statistical analyses of the TMA
results, an immunoreactivity score (IRS) was calculated by dividing the
sum of the individual staining intensities observed in the tissue cylin-
ders of a single case by the number of cylinders available from each case.
The IRS ranged from 0 to 3.
Statistics
Tables 2 and 3 present a summary of the analyzed medical param-
eters in form of mean ± SD or frequency distributions for discrete
parameters, respectively. The mean comparisons were carried out using
the two-sample t-test (the Satterthwaite approximation to compute
the degree of freedom). The correlations between SPARC expression
and tumor classification were evaluated using Fisher exact test. Sur-
vival times were evaluated by the log-rank test, and the results are
presented with Kaplan-Meier curves. All statistical decisions were made
2-tailed with a critical probability of α = 5% without α adjustment.
For that reason, the results should be interpreted in an exploratory
Table 1. Differential Expression of mRNA in a Patient with Metastatic Gastric Cancer.
Upregulated in the Lymph Node Metastasis Fold Change Factor Downregulated in the Lymph Node Metastasis Fold Change Factor
HLA-DR antigens associated invariant chain (p33) 5.1 Desmin 6.2
hcerN3 gene mRNA for N snRNP associated protein 4.9 20-kDa myosin light chain (MLC-2) 5.7
(23k/2) ubiquitin-conjugating enzyme UbcH2 4.9 22-kDa smooth muscle protein (SM22) 5.3
Lymph node homing receptor 4.8 Gastricsin 5.1
Immunoglobulin light-chain variable region (lambda IIIb subgroup)
from IgM rheumatoid factor
4.5 2′,3′-cyclic nucleotide 3′-phosphodiesterase 4.6
Ribosomal protein L32 4.2 Urokinase plasminogen activator receptor 4.3
Ribosomal protein S25 4.1 NRD1 convertase 4.2
Ribosomal protein L29 (humrpl29) 4.0 Neurogranin (RC3) 4.1
Ig rearranged light-chain mRNA V region 3.9 MOP4 3.8
Neuropeptide Y-like receptor 3.7 Antizyme inhibitor 3.8
H5, and platelet glycoprotein Ib beta chain 3.7 Carbonic anhydrase IV 3.7
Translationally controlled tumor protein 3.6 (Clone pGHSCBS) cystathionine beta-synthase subunit (CBS) 3.6
Prothymosin alpha 3.3 Transducin (beta) like 1 protein 3.4
Prothymosin alpha mRNA (ProT-alpha) 3.2 “HMG-Y protein isoform mRNA (HMGI gene); clone 11D” 3.1
Thymosin beta-4 3.0 Endothelial-monocyte activating polypeptide II 3.1
LERK5 (LERK5) 3.0 KIAA0411 3.0
Elongation factor 1-alpha 1 (PTI-1) 2.9 Treacher Collins syndrome (TCOF1) 2.9
Wilm tumor–related protein (QM) 2.8 Type 1 inositol 1,4,5-trisphosphate receptor 2.8
Ribosomal protein (homologous to yeast S24) 2.6 Vascular smooth muscle alpha-actin 2.6
KIAA0130 gene 2.6 Reelin (RELN) 2.6
Immunoglobulin kappa light chain 2.6 Voltage-dependent anion channel isoform 1 (VDAC) 2.4
GDP dissociation inhibitor beta 2.5 Bleomycin hydrolase 2.3
Ribosomal protein 2.5 K12 protein precursor 2.2
alpha 2 delta Calcium channel subunit isoform II 2.4 Ninjurin-1 2.1
Visinin-like peptide 1 homolog 2.4 KIAA 0207 gene 2.1
SPARC/osteonectin 2.3 Hepatoma-derived growth factor 2.1
Signal-transducing guanine nucleotide-binding regulatory (G)
protein beta subunit
2.2 Redox factor 2.0
PLSTIRE for serine/threonine protein kinase 2.1 Prolyl 4-hydroxylase beta-subunit 2.0
5′-fragment for vimentin N-terminal fragment 2.1 alpha-1-Antichymotrypsin 1.9
beta 2-Microglobulin 2.0 Procarboxypeptidase B 1.8
beta 2-mu, beta 2-Microglobulin 1.9
Translationally controlled tumor protein 1.8
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manner. To support the interpretation, P values of the statistical tests
were added in Tables 2 and 3. Statistical analyses were carried out with
SPSS 15.0 (SPSS, Inc, Chicago, IL) or SAS 9.1 (SAS Institute, Inc,
Cary, NC).
Results
Gene Array and RT-PCR
Homogenized tissue samples were obtained from the primary tu-
mor and the corresponding lymph node metastasis from a 69-year-
old patient with a poorly differentiated, intestinal-type gastric cancer.
Among the 62 genes studied, 32 were upregulated and 30 were
downregulated (Table 1). The mean fold change factors were 3.2
(range = 1.8-5.1) for the upregulated genes and 3.4 (range = 1.8-
6.2) for the downregulated genes. From the upregulated genes, we
selected SPARC for further validation studies because SPARC had
been shown to be involved in tumor progression [11–17], although
only limited data were available for gastric cancer. Furthermore,
monoclonal antibodies were available commercially to further test
the putative significance of SPARC on the translational level.
SPARC mRNA in Gastric Tissue and Gastric Cancer
Cell Lines
As shown in Figure 1, SPARC mRNA was found in the primary
intestinal-type gastric cancers of an independent set of five random
patients. The quantitative real-time RT-PCR data were used to com-
pare the expression level of SPARC mRNA in nonmalignant speci-
mens with the corresponding gastric cancers as well as the lymph
node metastases. The SPARC mRNA values were normalized against
the results for β-actin mRNA from the same samples. The average
amount of SPARC mRNA from the cancerous tissue was 2.17-fold
higher than that in noncancerous tissue, and at the afflicted lymph
nodes, it was increased approximately 8.52-fold (Figure 1A). How-
ever, because of the small sample number, this did not reach statis-
tical significance.
SPARC mRNA expression was examined in five different gastric
cancer cell lines. SPARC mRNA was found only in the NCI-N87
gastric cancer cell line. AGS, KATOIII, MKN28, and MKN45 did
not express SPARC mRNA. The differences in the expression of
SPARC in homogenized ex vivo gastric cancer tissue enclosing the
epithelial and nonepithelial components of tumor tissue and gastric
cancer cell lines lead to the conjecture that SPARC in tumor tissue
may arise from a cell type other than malignant epithelial cells
(Figure 1B).
Immunohistochemistry on Large Tissue Sections
To evaluate where and which cells express SPARC in gastric cancer,
we performed immunohistochemistry on 40 gastric tissue specimens
and their corresponding lymph node metastases. The samples were ob-
tained from both diffuse-type (20 cases) and intestinal-type (20 cases)
gastric cancers, with both cohorts comparable in age (67.7 years vs
62.7 years; not statistically significant) and sex. Each block contained
both noncancerous and cancerous tissues. We examined the expression
of SPARC in the nonneoplastic mucosa and surface epithelium, the
primary carcinomas, and the corresponding lymph node metastases.
SPARC was more commonly expressed in gastric cancer cells (30
patients, 75%) than in nonneoplastic surface epithelium (0%). Inter-
estingly, SPARC was expressed more commonly (20 intestinal type,
100%; 18 diffuse type, 90%) in the cells of the desmoplastic stroma
surrounding the tumor cells than in the tumor cells themselves
(Figure 2). The immunoreactivity in the intestinal cancer was mild
in 7 (35%), moderate in 11 (55%), and strong in 2 (10%) cases. Dif-
fuse gastric cancer cells showed a mild reaction in 8 (40%), moderate in
9 cases (45%), and strong in 1 (5%) case. A gradient of SPARC ex-
pression was found in 30 cases (17 intestinal type and 13 diffuse
Figure 1. Quantitative RT-PCR analysis of SPARCmRNA expression.
Total RNA was extracted from the human gastric cancer cell lines
(L-R: MKN28, MKN45, AGS, NCI-N87, KATO III) or from tissue sam-
ples of gastric cancer (TU), lymph node metastases (LN), and cor-
responding nonneoplastic tissue (NT) from five separate patients.
(A) Using fluorescence-mediated quantitative real-time RT-PCR and
product-specific primer, themRNA copy number for SPARCwas cal-
culated and normalized against the expression levels of β-actin to
account for any variability in RNA amounts or integrity (upper panel).
(B) SPARC mRNA was only found in the NCI-N87 gastric cancer cell
line (N87).ASPARC-positivegastric tumor servedasacontrol (control).
(C) β-Actin mRNA served as loading control.
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type) with a prominent immunoreaction of stromal cells at the invasion
front of the primary gastric cancers and decreased staining intensity in
the tumor center. The stromal cells of the nonneoplastic mucosa also
frequently expressed SPARC (36, 90%). However, the immuno-
reaction was weaker than in the cells of the desmoplastic stroma.
SPARC was not observed in the smooth muscle cells of either the mus-
cularis mucosae or muscularis propria.
The immunohistochemical analysis of SPARC expression in the
corresponding lymph node metastases showed a similar staining pat-
tern as the primary tumor. SPARC was expressed in carcinoma cells
as well as in the cells of the desmoplastic stroma (Figure 2). Again,
staining of cells of the desmoplastic stroma was more intense com-
pared with staining of the epithelial cancer cells.
Immunohistochemistry on TMA Sections
To determine whether the expression of SPARC in primary gastric
cancers correlates with clinicopathologic parameters, sections from
TMAs with samples from 152 gastric cancers were stained with anti–
SPARC antibody. Staining intensities were given as an IRS ranging
from 0 to 3 (Table 2). Similar to the large tissue sections, SPARC
was found in gastric cancer cells (11 cases, 7.0%; mean IRS = 0.029 ±
0.129, range = 0-1.2), the stromal cells of the desmoplastic stroma
Figure 2. Immunohistochemical analysis of SPARC expression in whole tissue sections. Formalin-fixed and paraffin-embedded tissue
sections were immunostained with anti-SPARC antibodies and counterstained with hematoxylin. A faint SPARC immunostaining was
found in the apical region of foveolar epithelium (A; arrows). Although intestinal type tumor cells were frequently immunonegative, the
stromal cells within and surrounding the tumor (B, C) showed staining of variable intensity: mild to moderate staining was found in the
tumor center (B) and strong staining was observed in the invasion front (C) and lymph node metastases (D). All pictures from panels A to
D were taken from the same section. Omission of the primary antibody served as a negative control (E).
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(146, 96%; mean IRS = 1.251 ± 0.685, range = 0-3.0), and occasionally
in the nonneoplastic foveolar epithelium (2, 2%; mean IRS = 0.004 ±
0.032, range = 0-0.300], and stromal cells of the nonneoplastic mucosa
(46, 31%; mean IRS = 0.1 ± 0.19, range = 0-1.0; Figure 3). The
frequencies and IRS of the SPARC expression are summarized in
Tables 2 and 3.
Correlation of SPARC Expression with
Clinicopathologic Parameters
Statistical analyses were carried out to evaluate correlations between
SPARC expression assessed in TMAs (given either as mean IRS, IRS
0 vs >0, and IRS <1 vs ≥1) and various clinicopathologic parameters
(Tables 2 and 3).
The differences in the mean IRS were highly significant (P < .01)
between the following: epithelial cancer cells versus nonneoplastic
foveolar epithelium; desmoplastic stroma versus stromal cells of the non-
neoplastic mucosa; desmoplastic stroma of intestinal-type versus desmo-
plastic stromal of diffuse-type gastric cancer. In addition, the IRS of
SPARC in cells of the desmoplastic stroma highly significantly correlated
with tumor type (P = .002).
The IRS of SPARC was categorized and divided into two groups:
0 versus >0 and <1 versus ≥1, respectively (Table 2). Only the N category
correlated significantly with the IRS <1 versus ≥1 of cells of the desmo-
plastic stroma, whereas a nonsignificant difference (P = .064) was noted
for the tumor type. No other variable, for example, age, sex, T or M
category, UICC tumor stage, or tumor grade of the entire study popu-
lation, that is, including intestinal- and diffuse-type gastric cancers,
correlated with the IRS of SPARC in either tumor cells or stromal cells.
The correlation between SPARC expression of stromal cells and
clinicopathologic parameters was then analyzed separately in intestinal-
and diffuse-type gastric cancers. Interestingly, in intestinal-type gastric
cancers, the mean IRS of SPARC in cells of the desmoplastic stroma
correlated highly significantly with the T category (P = .002), N cate-
gory (P = .008), and UICC tumor stage (P = .003; Table 3). No corre-
lations were found for diffuse-type gastric cancer.
SPARC Survival Analysis
Univariate analysis showed that SPARC expression in stromal cells of
intestinal-type gastric cancers was associated with a decreased patient
survival. However, because of low patient numbers (n = 41), this did
not reach statistical significance (P = .279; Figure 4). As a control for
our study population, we also analyzed the influence of nodal spread on
patient survival. A significant negative correlation was found between
patient survival and the presence of lymph node metastases, with pa-
tients with a negative nodal status (N = 0) living longer than those with
N > 0 (P < .01). The difference remained significant for intestinal-type
Table 2. Correlation of the SPARC Expression in TMAs with Various Clinicopathologic Characteristics.
Gastric Cancer Patients Total Tumor P SPARC 0 vs >0 Stroma P SPARC 0 vs >0 Stroma IRS ≥ 1 P IRS ≥1 vs <1
Patients [n (%)] 152 (100) 11 (7.0) 146 (96.1) 104 (68.4)
Age [mean (SD)] 65.03 (12.54) 65.94 (13.03)
Mean age SPARC-positive [years (n)] 66.79 (2) .748 65.03 (57) 65.94 (46) .198
Mean age SPARC-negative [years (n)] 64.96 (55) – 61.21 (11)
Mean survival of SPARC-positive patients [days (n)] 379.5 (2) .932* 548.5 (57) – 553.7 (48) .363*
Mean survival of SPARC-negative patients [days (n)] 554.4 (57) – 525.73 (11)
Sex
Men [n (%)] 92 (60.5) 7 (7.6) 1.000 89 (96.7) .681 62 (67.4) .856
Women [n (%)] 60 (39.5) 4 (6.7) 57 (95.0) 42 (32.6)
Tumor type
Intestinal [n (%)] 102 (67.1) 10 (9.8) .102 99 (97.1) .395 75 (73.5) .064
Diffuse [n (%)] 50 (32.9) 1 (2.0) 47 (94.0) 29 (58.0)
T category
pT1 [n (%)] 15 (9.9) 3 (20.0) .266 14 (93.3) .737 8 (53.3) .121
pT2A [n (%)] 19 (12.5) 2 (10.5) 19 (100) 16 (84.2)
pT2B [n (%)] 48 (31.6) 3 (6.3) 45 (93.8) 28 (58.3)
pT3 [n (%)] 60 (39.5) 3 (5.0) 58 (96.7) 45 (75.0)
pT4 [n (%)] 10 (6.6) 0 (0.0) 10 (100) 7 (70.0)
N category
pN0 [n (%)] 42 (27.6) 6 (14.3) .198 41 (97.6) .248 23 (54.8) .016
pN1 [n (%)] 52 (34.2) 1 (1.9) 51 (98.1) 43 (82.7)
pN2 [n (%)] 36 (23.8) 3 (8.3) 32 (88.9) 21 (58.3)
pN3 [n (%)] 19 (12.5) 1 (5.3) 19 (100) 15 (78.9)
pNX [n (%)] 3 (2.0) 0 (0.0) 3 (100) 2 (66.7)
M category
pM0 [n (%)] 1 (0.7) 0 (0.0) .713 1 (100) 1.000 1 (100) .267
pM1 [n (%)] 26 (17.1) 1 (3.9) 25 (96.2) 21 (80.8)
pMX [n (%)] 125 (82.2) 10 (8.0) 120 (96.1) 82 (65.69)
UICC tumor stage
Stage I [n (%)] 36 (23.7) 6 (16.7) .022† 35 (97.2) .140 20 (55.6) .324
Stage II [n (%)] 35 (23.0) 0 (0.0) 35 (100) 25 (71.4)
Stage III [n (%)] 39 (25.8) 3 (7.7) 35 (89.7) 28 (71.8)
Stage IV [n (%)] 42 (27.6) 2 (4.8) 41 (97.6) 31 (73.8)
Grading
G 1 [n (%)] 3 (2.0) 0 (0.0) .747† 3 (100) 1.000† 0 (0.0) .854†
G 2 [n (%)] 46 (30.3) 4 (8.7) 44 (95.7) 33 (71.7)
G 3 [n (%)] 94 (61.8) 7 (7.4) 90 (95.7) 68 (72.3)
G 4 [n (%)] 9 (5.9) 0 (0.0) 9 (100) 3 (13.3)
*P value of the log-rank test.
†P value of a 2 × 2 contingency table.
Boldface font indicates statistically significant results.
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gastric cancers (P = .046) and, again, because of low case numbers, was
not significant for diffuse-type gastric cancers (P = .125; not shown).
Because the expression of SPARC in cells of the desmoplastic stroma
correlated with the N category (Table 2) and because patient sur-
vival is influenced by nodal status, we performed a Cox regression
with a variable reduction procedure (Wald forward) using nodal status
(N = 0 vs N > 0) and SPARC expression as covariables. This procedure
showed that only the nodal status is of importance for this model for
all patients (P = .027) as well as patients with intestinal-type gastric cancer
(P = .064).
Discussion
In this study, we show that secreted protein acidic and rich in cysteine
(SPARC; syn. osteonectin, BM-40) is differentially expressed in meta-
stastic gastric cancer, localized primarily in the stromal cells of the desmo-
plastic stroma surrounding the epithelial tumor cells, and correlates
Figure 3. Immunohistochemical analysis of SPARC expression in TMAs. Formalin-fixed and paraffin-embedded tissue sections from
TMAs were immunostained with anti-SPARC antibodies and counterstained with hematoxylin. SPARC was expressed most strongly
in stromal cells of the desmoplastic stroma of intestinal-type gastric cancer (A), less common in the stromal cells of diffuse type cancer
(B), and occasionally, a cytoplasmic staining was found in intestinal-type tumor cells (C; arrows). Connective tissue and gastric foveolar
epithelium were almost always negative (D).
Table 3. Evaluation of the Expression of SPARC (Given as Mean IRS) in TMAs.
Cell Type No. of Cases (n)* Mean IRS ± SD (Range) P, t-Test
Nonneoplastic foveolar epithelium 122 0.004 ± 0.032 (0-0.300)
Stromal fibroblasts of nonneoplastic stomach (total) 148 0.100 ± 0.1900 (0-1.00)
Cancer cells
All gastric cancers 152 0.029 ± 0.129 (0-1.20)
Diffuse-type gastric cancer 50 0.010 ± 0.071 (0-0.50) .138
Intestinal-type gastric cancer 102 0.037 ± 0.149 (0-1.20)
Cells of the desmoplastic stroma
All gastric cancers 152 1.251 ± 0.685 (0-3.00)
Diffuse-type gastric cancers 50 1.012 ± 0.608 (0-2.30) .002
Intestinal-type gastric cancers 102 1.369 ± 0.693 (0-3.00)
Intestinal-type gastric cancers (pT1) 10 0.860 ± 0.427 (0.2-1.5) .002
Intestinal-type gastric cancers (pT2-pT4) 92 1.424 ± 0.695 (0-3.00)
Intestinal-type gastric cancers (pN0) 32 1.122 ± 0.562 (0.2-2.20) .008
Intestinal-type gastric cancers (pN1-pN3) 70 1.481 ± 0.726 (0-3.00)
Intestinal-type gastric cancers (UICC stage I) 28 1.079 ± 0.531 (0.2-2.20) .003
Intestinal-type gastric cancers (UICC stage II-IV) 74 1.478 ± 0.718 (0-3.00)
*The TMAs did not enclose all histoanatomic structures equally.
316 SPARC in Gastric Cancer Franke et al. Translational Oncology Vol. 2, No. 4, 2009
significantly in intestinal-type gastric cancer with the local tumor growth,
nodal spread, and tumor stage. On the basis of our results, we hypothe-
size that SPARC is involved in the pathology of gastric cancers.
SPARC is a calcium-binding glycoprotein with three domains: the
N-terminal acidic domain with a low affinity for calcium, a copper-
binding domain, and the C-terminal, calcium-binding region [18].
The single-copy gene is located on chromosome 5, and the secreted gene
product has a molecular weight of 43 kDa. It was first described as being
a constituent of human and bovine bones [19], but in the embryo,
SPARC is expressed in all germ lines and is also found in the skin, heart,
kidney, lung, testicle, thyroid, and intestine.
Matricellular proteins, such as SPARC, play important roles in the
remodeling of the extracellular matrix without being a structural com-
ponent of it. Several other matricellular proteins, including SPARC-
like 1, testican 1 to 3, SMOC 1 to 2, CCN 1 to 6, thrombospondin
1 to 5, osteopontin, tenascin-C, tenascin-X, and galectin, have been re-
cently identified [20]. All these proteins exhibit a high level of expression
during embryogenesis and minimal or no expression in the adult organ-
ism, with reexpression occurring after tissue injury, inflammation, and
tumorigenesis [21,22]. The up-regulation of SPARC observed in this
study in gastric cancer tissues, its expression in epithelial and stromal
cells, and the increased expression at the invasion front, where tissue re-
modeling is most prominent, are in line with previous observations and
its known biologic functions as matricellular protein.
SPARC in Gastric Cancer
Our study also supports previous investigations regarding differential
expression of SPARC in gastric cancer, including three groups using a
gene array–based approach [23–25]. In keeping with our own observa-
tions, all previous studies collectively reported an up-regulation of
SPARC on transcriptional, translational, or both levels in gastric cancer
compared with nonneoplastic mucosa [23–27]. However, there are dis-
crepancies regarding the histoanatomic distribution of SPARC in the
stomach. Wewer et al. [27] described a differential expression of
SPARC in the epithelial and stromal compartments of six gastric cancer
specimens. Maeng [26] found SPARC only in stromal cells of their 31
gastric cancer patients and not in any epithelial cancer cell. Wang et al.
Figure 4. Overall survival. Kaplan-Meier curves depicting overall patient survival according to nodal status (A; P= .010), expression of SPARC
(<1 vs≥1) in cells of thedesmoplastic stroma in all patients (B;P= .537), patientswith intestinal-typegastric cancer (C;P= .279) and patients
with diffuse-type gastric cancer (D; P = .657).
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[25] also found a differentially expressed SPARC in gastric cancer
patients as assessed by gene array analysis, quantitative RT-PCR, and
immunostaining. However, Wang et al. [25] found SPARC in normal
gastric epithelial cells, marked in gastric cancer cells, and in low levels in
the surrounding stromal cells of the tumor tissue. These discrepancies
cannot be fully explained. The size of the study populations, the choice
of primary antibodies, antibody dilutions, staining protocols, and tissue
specimens may all contribute to variable staining patterns among non-
neoplastic epithelium, cancer, and stromal cells. Even in our study,
which until now presents the largest series of gastric cancer patients
investigated for SPARC expression, we observed a discrepancy between
nonneoplastic epithelium in large tissue sections and sections from
TMA. The latter may be explained by the fact that nonneoplastic
mucosa in large tissue sections was usually adjacent to the tumor area,
which may have influenced SPARC expression. Our sections from
TMA included nonneoplastic mucosa more distant from the primary
tumor site and may explain the reduced expression of SPARC. Indeed,
we noticed in the large tissue sections that mucosa adjacent to the tumor
expressed SPARC more commonly than mucosa at a distance. These
details were not considered in previous studies and may have influenced
the results.
SPARC in Tumor Biology
Our immunohistochemical studies showed that SPARC expression
in cells of the desmoplastic stroma highly significantly correlated with
tumor type, favoring the intestinal type of gastric cancer. Similar ob-
servations were previously made in breast cancer. Watkins et al. [28]
showed that ductal adenocarcinomas of the breast with a cohesive tumor
growth pattern, similar to the intestinal-type gastric cancer, had higher
SPARC levels than lobular breast cancers, with a decohesive growth
pattern resembling that of diffuse-type gastric cancer. In addition, many
studies have provided evidence that the desmoplastic tumor stroma is
not a passive mold for the epithelial tumor cells, but influences tumor
cell differentiation, proliferation, apoptosis, and mobility, thereby play-
ing a prominent role in tumor biology [29–31]. It is to be expected that
the expression of SPARC in cells of the desmoplastic stroma of gastric
cancer correlates with the histologic tumor type. However, on the basis
of our data, the nature of the interaction remains obscure. SPARC ex-
pression in stromal cells may depend on the histologic type of the tumor
and vice versa. Indeed, transfection of melanocytes with SPARC was as-
sociated with a change of their phenotype from dendritic to fibroblast-
like [32]. Mechanisms of SPARC action were also examined in SPARC
wild-type and SPARC knockout mice injected with ovarian cancer cells.
Wild-type mice had higher levels of tissue inhibitor of matrix metallo-
proteinases 1 and 2 and reduced levels of matrix metalloproteinases,
leading to decreased vascular endothelial growth factor levels, a reduced
activation of integrins on the cell surface, and an increased deadhesion
of the tumor cells [33,34]. A similar mechanism may be active in the
diffuse type of gastric cancer, where a reduced expression of SPARC
in stromal cells may support a decohesive phenotype.
The correlation found in this study between the expression of
SPARC in stromal cells and the local tumor growth, metastasis for-
mation, and tumor stage is reinforced by similar results in both gas-
tric cancer and other tumor types [35]. Other groups also studied the
correlation between the expression of SPARC, either on the tran-
scriptional [25] or the translational level [23], with various clinico-
pathologic patient characteristics. They found a correlation between
SPARC expression and local tumor growth (T category), nodal spread
(N category), and UICC tumor stage, which is in line with our own
findings. However, in this context, it is worth noting that Wang et al.
[25] used tissue homogenates and correlated overall SPARC mRNA
levels in tumor tissue without separating into the epithelial and stromal
compartment. Oue et al. [23] studied gastric cancer patients with a
special focus on atomic bomb survivors. Both did not find any corre-
lation between SPARC expression and tumor type, that is, intestinal-
and diffuse-type gastric cancer. This may also be related to the different
study populations and different methods used and may explain this
particular discrepancy to our own result. Wang et al. [25] studied only
43 patients, which may have been too few to find a difference on the
transcriptional level between intestinal- and diffuse-type gastric cancer.
Despite including more patients, Oue et al. [23] mixed gastric cancer
with and without radiation exposure. Patients exposed to radiation
were shown to have lower levels of SPARC in their tumor tissue com-
pared with non–radiation-exposed individuals. Nevertheless, a recent
article demonstrated a correlation of SPARC mRNA and protein ex-
pression with the World Heath Organization’s grade in meningioma
[36], indicating that there are valid grounds for a correlation between
SPARC expression and tumor type.
SPARC plays a role in various biologic functions, most of which are
important capabilities for local tumor growth and metastasis formation.
Deregulation of any of these processes, which include cellular morphol-
ogy, cell adhesion and deadhesion, migration, apoptosis, angiogenesis,
and tissue remodeling, would contribute to the invasion and metastasis
of tumor cells [37–45]. It has been shown that SPARC increases cell
mobility and migratory behavior in glioblastoma [46], kidney [47], and
prostate cancer cells, partly in a concentration-dependent manner [48].
Invasion of epithelial tumor cells is characterized and indispensably
associated with the formation of the desmoplastic stroma, which pro-
vides a tumor biologic rationale for the increased expression of SPARC
at the invasion front, as it was found in our series of large gastric cancer
tissue sections. Tissue remodeling is most prominent at this transitional
interface, where we found the highest expression of SPARC. Local
tumor growth also depends on a sufficient supply of oxygen and nu-
trients, and neoangiogenesis is one of several hallmarks of malignancy.
Depending on the local concentration and the primary structure of its
proteolytic fragments generated in situ, SPARC may either promote or
inhibit neovascularization [18,46,49–52]. Indeed, in our study, the ex-
pression of SPARC correlated in the intestinal-type gastric cancer with
the local tumor growth and at least supports the contention that
SPARC may have a proangiogenic effect in gastric cancer.
In summary, including our own study, there is now ample tran-
scriptional and translational evidence for a differential expression of
SPARC in gastric cancer tissue. The expression of SPARC correlates
with the tumor phenotype, local tumor growth, nodal spread, andUICC
tumor stage. On the basis of our observations and those made by others,
we hypothesize that SPARC is a promising novel target for the treatment
of gastric cancer.
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